Filing Information

Inventor(s)	Mark J. Mamula ·
Assignee(s)	Yale University ·  View assignee updates
Attorney/Agent(s)	Todd E. Garabedian · Wiggin and Dana LLP ·
Primary Examiner	Karen A Canella ·
Application Number	US10613272
Filing date	07/03/2003
Issue date	12/01/2009
Predicted expiration date	11/13/2024
Patent term adjustment	1044
U.S. Classifications	424/204.1  · 530/402  · 424/277.1  · 530/403  · 424/234.1  ·
International Classifications	A61K3900  · A61K3902  · A61K3912  · C08H100  ·
Kind Code	B1
Related U.S. Application Data	CROSS-REFERENCE TO RELATED APPLICATIONS This application is a Continuation-in-Part of International Application No. PCT/US02/00336, filed Jan. 4, 2002, which claims the benefit of U.S. Provisional Application No. 60/259,765 filed Jan. 4, 2001. These applications are herein incorporated by reference in their entireties.

Patent Family

Abstract

The present invention is directed to a method of enhancing the immune response of a patient relative to the normal immune response, by administering isoaspartyl-modified proteins, peptides, or cells, to a patient. The present invention is also directed to vaccines containing the isoaspartyl-modified proteins, peptides, or cells, as well as antibodies reactive with the isoaspartyl-modified proteins, peptides, or cells.

Independent Claims | See all claims (10)

1. 1. A method of enhancing the humoral immune response of a patient relative to the normal humoral immune response, comprising the steps of: growing cells containing a tumor antigen, a bacterial protein, or a viral protein under conditions wherein an aspartic acid residue or an asparigine residue in said tumor antigen, said bacterial protein, or said viral protein is converted to an isoaspartic acid residue to produce an isoaspartic acid-containing tumor antigen, an isoaspartic acid-containing bacterial protein, or an isoaspartic acid-containing viral protein, said conditions comprising exposing said cells to 15-30 μM adenosine dialdehyde at approximately 25-40° C. for 1-5 days; optionally isolating said isoaspartic acid-containing tumor antigen, an isoaspartic acid-containing bacterial protein, or an isoaspartic acid-containing viral protein; and administering said cells or said isolated isoaspartic acid-containing tumor antigen, an isoaspartic acid-containing bacterial protein, or an isoaspartic acid-containing viral protein to said patient to enhance the humoral immune response of said patient.
2. 6. A method of enhancing the humoral immune response of a patient relative to the normal humoral immune response, comprising the steps of: providing a tumor antigen, a bacterial protein, or a viral protein, or a fragment thereof, wherein each of said tumor antigen, a bacterial protein, or a viral protein, or a fragment thereof comprises an aspartic acid residue or an asparigine residue; treating said tumor antigen, a bacterial protein, or a viral protein, or a fragment thereof to convert said aspartic acid residue or said asparigine residue to an isoaspartic acid residue to produce an isoaspartic acid-containing tumor antigen, an isoaspartic acid-containing bacterial protein, an isoaspartic acid-containing viral protein, or isoaspartic acid-containing fragment thereof; assaying for levels of isoaspartyl modification in the treated tumor antigen, bacterial protein, viral protein, or fragment thereof; administering the isoaspartic acid-containing tumor antigen, isoaspartic acid-containing bacterial protein, isoaspartic acid-containing viral protein, or isoaspartic acid-containing fragment thereof to said patient to elicit said enhanced humoral immune response.